Ibuprofen and Coated side effects: what 42,249 FDA adverse event reports show
Drug class
Nonsteroidal Anti-inflammatory Drug
Label matched
Ibuprofen (Ibuprofen)
Who reports
42,249 reports · 40% serious · 1,242 with death outcome · 70% female
Used for
Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
What it is
DESCRIPTION Ibuprofen tablets USP contain the active ingredient ibuprofen, which is (±) - 2 - ( p - isobutylphenyl) propionic acid. Ibuprofen is a white to off-white, crystalline powder with a.
Boxed warning
Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ].
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,142 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Swollen joint count | 32 | 74.1 51.1–107.4ROR 74.1 · calibrated p 2e-6 ✓ | 62.2 EB05 46.1 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=32 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Grip strength | 26 | 62.6 41.6–94.1ROR 62.6 · calibrated p 7e-6 ✓ | 53.5 EB05 38.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=26 · 100% clinician | not reported in cached trials |
| Product coating issue | 83 | 44.0 35.1–55.0ROR 44.1 · calibrated p 4e-5 ✓ | 40.1 EB05 33.4 · IC025 +4.7 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Product difficult to swallow | 61 | 31.2 24.1–40.4ROR 31.2 · calibrated p 3e-4 ✓ | 29.2 EB05 23.5 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Poor quality drug administered | 357 | 28.5 25.6–31.7ROR 28.7 · calibrated p 3e-4 ✓ | 26.9 EB05 24.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=42 · 94% consumer | not reported in cached trials |
| C-reactive protein | 39 | 22.2 16.1–30.6ROR 22.3 · calibrated p 0.002 ✓ | 21.1 EB05 16.1 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=39 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Foreign body | 172 | 22.0 18.9–25.6ROR 22.1 · calibrated p 0.001 ✓ | 21.0 EB05 18.5 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=28 · 100% consumer | NCT00346216: 1/7,933 (0.0%) on Ibuprofen and Coated (serious AE) |
| Foreign body in respiratory tract | 54 | 21.1 16.0–27.6ROR 21.1 · calibrated p 0.002 ✓ | 20.1 EB05 16.0 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=16 · 100% consumer | not reported in cached trials |
| Deep vein thrombosis postoperative | 79 | 20.8 16.6–26.0ROR 20.8 · calibrated p 0.002 ✓ | 19.9 EB05 16.5 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=79 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Reaction to drug excipients | 75 | 17.4 13.9–22.0ROR 17.5 · calibrated p 0.004 ✓ | 16.8 EB05 13.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | 86% consumer | not reported in cached trials |
| Drug effective for unapproved indication | 939 | 16.4 15.4–17.5ROR 16.8 · calibrated p 0.004 ✓ | 15.9 EB05 15.1 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | 100% consumer | not reported in cached trials |
| Drug effect delayed | 143 | 15.9 13.5–18.8ROR 15.9 · calibrated p 0.006 ✓ | 15.4 EB05 13.4 · IC025 +3.6 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Retinitis | 50 | 15.3 11.5–20.3ROR 15.3 · calibrated p 0.007 ✓ | 14.7 EB05 11.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=50 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 59 | 14.9 11.5–19.3ROR 14.9 · calibrated p 0.008 ✓ | 14.4 EB05 11.5 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=58 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Product shape issue | 27 | 14.7 10.0–21.6ROR 14.7 · calibrated p 0.010 ✓ | 13.9 EB05 9.8 · IC025 +2.9 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Product commingling | 30 | 14.6 10.2–21.0ROR 14.6 · calibrated p 0.010 ✓ | 13.9 EB05 9.9 · IC025 +2.9 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Facet joint syndrome | 86 | 13.9 11.2–17.2ROR 13.9 · calibrated p 0.010 ✓ | 13.4 EB05 11.2 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=85 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 1/7,933 (0.0%) on Ibuprofen and Coated (serious AE) |
| Blood pressure diastolic abnormal | 70 | 13.9 10.9–17.6ROR 13.9 · calibrated p 0.011 ✓ | 13.4 EB05 10.9 · IC025 +3.2 3/3 methods agree | Lab value / disease marker | serious n=63 · 100% clinician | not reported in cached trials |
| Blood pressure systolic abnormal | 67 | 13.7 10.7–17.4ROR 13.7 · calibrated p 0.011 ✓ | 13.2 EB05 10.7 · IC025 +3.2 3/3 methods agree | Lab value / disease marker | serious n=62 · 100% clinician | NCT00346216: 1/7,933 (0.0%) on Ibuprofen and Coated (serious AE) |
| Lupus vulgaris | 32 | 13.7 9.6–19.4ROR 13.7 · calibrated p 0.012 ✓ | 13.0 EB05 9.4 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=32 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Dislocation of vertebra | 57 | 13.0 10.0–16.9ROR 13.0 · calibrated p 0.014 ✓ | 12.5 EB05 9.9 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=57 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| X-ray abnormal | 44 | 12.5 9.3–16.9ROR 12.5 · calibrated p 0.016 ✓ | 11.9 EB05 9.1 · IC025 +2.9 3/3 methods agree | Lab value / disease marker | serious n=44 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 65 | 10.5 8.2–13.5ROR 10.6 · calibrated p 0.029 ✓ | 10.1 EB05 8.1 · IC025 +2.9 3/3 methods agree | Lab value / disease marker | serious n=65 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Skin papilloma | 79 | 9.9 8.0–12.4ROR 10.0 · calibrated p 0.035 ✓ | 9.5 EB05 7.8 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=73 · ♀ 100% (drug 70%) | not reported in cached trials |
| Porphyria acute | 27 | 9.9 6.7–14.4ROR 9.9 · calibrated p 0.040 ✓ | 8.9 EB05 6.2 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=27 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Peripheral venous disease | 76 | 9.6 7.7–12.0ROR 9.6 · calibrated p 0.039 ✓ | 9.2 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=75 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 1/7,992 (0.0%) on Ibuprofen and Coated (serious AE) |
| Rheumatic fever | 82 | 9.5 7.6–11.8ROR 9.5 · calibrated p 0.041 ✓ | 9.1 EB05 7.5 · IC025 +2.8 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=82 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Product used for unknown indication | 23 | 9.3 6.2–14.0ROR 9.3 · calibrated p 0.050 ✓ | 8.2 EB05 5.6 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
| Foreign body in throat | 55 | 9.1 7.0–11.9ROR 9.1 · calibrated p 0.047 ✓ | 8.6 EB05 6.8 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=54 · 100% consumer | not reported in cached trials |
| Biliary dyskinesia | 31 | 9.1 6.4–13.0ROR 9.1 · calibrated p 0.051 | 8.3 EB05 6.0 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=31 · ♀ 100% (drug 70%) · 100% consumer | NCT00346216: 1/7,992 (0.0%) on Ibuprofen and Coated (serious AE) |
| Product taste abnormal | 235 | 8.8 7.7–10.0ROR 8.8 · calibrated p 0.049 ✓ | 8.6 EB05 7.7 · IC025 +2.9 3/3 methods agree | Reporting / coding artifact | serious n=35 · 94% consumer | not reported in cached trials |
| Bone erosion | 57 | 8.1 6.2–10.5ROR 8.1 · calibrated p 0.068 | 7.6 EB05 6.1 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=55 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 1/7,933 (0.0%) on Ibuprofen and Coated (serious AE) |
| Product size issue | 83 | 7.9 6.3–9.8ROR 7.9 · calibrated p 0.073 | 7.5 EB05 6.2 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | serious n=29 · 100% consumer | not reported in cached trials |
| Pre-existing condition improved | 97 | 7.7 6.3–9.4ROR 7.7 · calibrated p 0.076 | 7.4 EB05 6.2 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | 84% consumer | not reported in cached trials |
| C-reactive protein abnormal | 98 | 7.7 6.3–9.4ROR 7.7 · calibrated p 0.077 | 7.4 EB05 6.2 · IC025 +2.5 3/3 methods agree | Lab value / disease marker | serious n=97 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
| Therapeutic product effect variable | 57 | 7.5 5.8–9.7ROR 7.5 · calibrated p 0.085 | 7.1 EB05 5.6 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | 100% consumer | not reported in cached trials |
| Duodenal ulcer perforation | 107 | 7.3 6.1–8.9ROR 7.3 · calibrated p 0.089 | 7.0 EB05 6.0 · IC025 +2.5 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 10.5 · ♀ 100% (drug 70%) · 100% clinician | NCT00346216: 2/7,933 (0.0%) on Ibuprofen and Coated (serious AE) |
| Drug effect incomplete | 527 | 7.2 6.6–7.8ROR 7.3 · calibrated p 0.089 | 7.1 EB05 6.6 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious PRR 4.7 · 88% consumer | not reported in cached trials |
| Oral discomfort | 199 | 7.2 6.2–8.3ROR 7.2 · calibrated p 0.092 | 7.0 EB05 6.2 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=40 · 88% consumer | not reported in cached trials |
| Rheumatoid factor positive | 81 | 7.0 5.7–8.8ROR 7.1 · calibrated p 0.100 | 6.7 EB05 5.6 · IC025 +2.4 3/3 methods agree | Lab value / disease marker | serious n=81 · ♀ 100% (drug 70%) · 100% clinician | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Ibuprofen and Coated as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (7 of 40 signal terms matched).
- NCT00346216 — Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (N=24081, PHASE4; 1238 AE terms posted; arms: Celecoxib; Ibuprofen; Naproxen)
- NCT01789606 — Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet (N=1083, PHASE3; 60 AE terms posted; arms: Compliance Arm)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 6,781 | 2.6 2.5–2.6ROR 2.9 · calibrated p 0.673 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Reporting / coding artifact | serious PRR 2.2 · 84% consumer | not reported in cached trials |
| Fatigue (tiredness) | 2,691 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.812 | 1.7 EB05 1.7 · IC025 +0.7 | Not in label — unassessed | serious PRR 2.7 | NCT00346216: 2/7,992 (0.0%) on Ibuprofen and Coated (serious AE) |
| Nausea | 2,680 | 1.7 1.6–1.8ROR 1.7 · calibrated p 0.790 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 2.6 | NCT00346216: 3/7,992 (0.0%) on Ibuprofen and Coated (serious AE) |
| Headache | 2,568 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.999 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled adverse reaction exact term | serious PRR 3.0 | NCT00346216: 6/7,992 (0.1%) on Ibuprofen and Coated (serious AE) |
| Pain | 2,471 | 2.0 1.9–2.1ROR 2.1 · calibrated p 0.975 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled — boxed warning exact term | serious PRR 2.9 | NCT00346216: 7/7,992 (0.1%) on Ibuprofen and Coated (serious AE) |
| Diarrhoea (diarrhea) | 1,789 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.574 | 1.4 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | serious PRR 1.9 | NCT00346216: 8/7,992 (0.1%) on Ibuprofen and Coated (serious AE) |
| Product use in unapproved indication | 1,740 | 3.6 3.4–3.7ROR 3.7 · calibrated p 0.447 | 3.5 EB05 3.4 · IC025 +1.7 3/3 methods agree | Reporting / coding artifact | serious PRR 2.0 · 85% consumer | not reported in cached trials |
| Dizziness | 1,734 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.807 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 2.4 | NCT00346216: 5/7,992 (0.1%) on Ibuprofen and Coated (serious AE) |
| Arthralgia (joint pain) | 1,653 | 2.0 1.9–2.1ROR 2.0 · calibrated p 0.957 | 2.0 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | serious PRR 3.4 | NCT00346216: 33/7,992 (0.4%) on Ibuprofen and Coated (serious AE) |
| Off label use (used outside approved label) | 1,468 | 0.8 0.8–0.9ROR 0.8 · calibrated p 0.203 | 0.8 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 1.5 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 1,427 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.482 | 1.3 EB05 1.2 · IC025 +0.2 | Not in label — unassessed | serious PRR 1.8 | NCT00346216: 24/7,992 (0.3%) on Ibuprofen and Coated (serious AE) |
| Vomiting | 1,382 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.628 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | serious PRR 2.1 | NCT00346216: 7/7,992 (0.1%) on Ibuprofen and Coated (serious AE) |
| Malaise (feeling unwell) | 1,352 | 1.5 1.4–1.6ROR 1.5 · calibrated p 0.671 | 1.5 EB05 1.5 · IC025 +0.5 | Not in label — unassessed | serious PRR 2.0 | NCT00346216: 1/7,992 (0.0%) on Ibuprofen and Coated (serious AE) |
| Abdominal discomfort | 1,297 | 3.9 3.7–4.1ROR 4.0 · calibrated p 0.385 | 3.8 EB05 3.7 · IC025 +1.9 3/3 methods agree | Not in label — unassessed | serious PRR 3.8 · 76% consumer | NCT00346216: 1/7,992 (0.0%) on Ibuprofen and Coated (serious AE) |
| Rash | 1,237 | 1.4 1.3–1.5ROR 1.4 · calibrated p 0.595 | 1.4 EB05 1.4 · IC025 +0.4 | Labeled adverse reaction exact term | serious PRR 2.2 | NCT00346216: 1/8,030 (0.0%) on Ibuprofen and Coated (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Swollen joint count — n=32, PRR 74.1
- Grip strength — n=26, PRR 62.6
- Poor quality drug administered — n=357, PRR 28.5
- Foreign body — n=172, PRR 22.0 (also seen in trial arm)
- Foreign body in respiratory tract — n=54, PRR 21.1
- Deep vein thrombosis postoperative — n=79, PRR 20.8
- Reaction to drug excipients — n=75, PRR 17.4
- Retinitis — n=50, PRR 15.3
- Adjustment disorder with depressed mood — n=59, PRR 14.9
- Facet joint syndrome — n=86, PRR 13.9 (also seen in trial arm)
✓ A hand-written Bradford Hill causality assessment exists for this drug: Ibuprofen (NSAIDs) ↔ Gastrointestinal bleeding.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Ibuprofen and Coated?
In FDA FAERS, the most frequently co-reported reaction terms for Ibuprofen and Coated are fatigue, nausea, headache, pain, diarrhoea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Ibuprofen and Coated have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ].
Do FAERS signals prove that Ibuprofen and Coated causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 00872852-680a-41b3-901b-b991b12a176d, effective 20250214; matched on
openfda.generic_name.exact:"IBUPROFEN") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,182 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
IBUPROFEN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.